KaydedilenlerDerginizi ekleyin

Dergiler / The Anatolian Journal of Cardiology / 2017 / Cilt: 17 - Sayı: 1

Age and gender differences in Framingham risk score and metabolic syndrome in psoriasis patients: A cross-sectional study in the Turkish population

Ayşe Esra AKSU KOKU
ZEYNEP NURHAN SARAÇOĞLU
SELMA METİNTAŞ
İlham SABUNCU
Yıldız ÇETİN
Sayfa
66–72
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

There was no statistically significant relationship among MS, FRS, and psoriasis severity (p>0.05).Conclusion: The results of this study support the evaluation of cardiovascular risk assessment in female psoriasis patients with MS and in male and elderly psoriasis patients with FRS.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Psoriasis is associated with an increased frequency of cardiovascular risk factors.
📊
Temel Bulgular & Veri:This study aimed to evaluate the frequency of MS and FRS in psoriasis patients compared with a control group and investigate the differences between MS and FRS.Methods: This was a cross-sectional study involving 300 psoriasis patients and 177 controls.
💡
Sonuç & Katkı:There was no statistically significant relationship among MS, FRS, and psoriasis severity (p>0.05).Conclusion: The results of this study support the evaluation of cardiovascular risk assessment in female psoriasis patients with MS and in male and elderly psoriasis patients with FRS.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Psoriasis is associated with an increased frequency of cardiovascular risk factors. Metabolic syndrome (MS) and the Framingham risk score (FRS) are two different algorithms for evaluating cardiovascular risk. They include different features: waist circumference measurement is included in the MS criteria, whereas smoking, age, and gender are questioned in FRS. This study aimed to evaluate the frequency of MS and FRS in psoriasis patients compared with a control group and investigate the differences between MS and FRS.Methods: This was a cross-sectional study involving 300 psoriasis patients and 177 controls. MS, FRS, and disease severity were evaluated.Results: The frequency of MS was higher in females with psoriasis than in those in the control group (p=0.019). Females in the psoriasis group were more obese than those in the control group (p=0.036). FRS significantly differed between the patients and controls of age >60 years (p=0.006). The risk of hypertension in current and past smokers was higher in the psoriasis patients (OR=2.07 and 2.32-2.48, respectively) than in the control group. There was no statistically significant relationship among MS, FRS, and psoriasis severity (p>0.05).Conclusion: The results of this study support the evaluation of cardiovascular risk assessment in female psoriasis patients with MS and in male and elderly psoriasis patients with FRS.

🔖

Bu Makaleye Atıf Yap

KOKU, A. E. A., SARAÇOĞLU, Z. N., METİNTAŞ, S., SABUNCU, İ., ÇETİN, Y. (2017). Age and gender differences in Framingham risk score and metabolic syndrome in psoriasis patients: A cross-sectional study in the Turkish population. The Anatolian Journal of Cardiology, Cilt: 17 - Sayı: 1, 66–72. https://ajindex.com/articles/366719

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 2008; 7: 373-7.
  2. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichen- thal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-8.
  3. Sales R, Torres T. Psoriasis and metabolic syndrome. Acta Der- matovenerol Croat 2014; 22: 169-74.
  4. Takahashi H, Takahashi I, Honma M, Ishida-Yamamoto A, Iizu- ka H. Prevalence of metabolic syndrome in Japanese psoriasis patients. J Dermatol Sci 2010; 57: 143-4.
  5. Alsufyani MA, Golant AK, Lebwohl M. Psoriasis and the meta- bolic syndrome. Dermatol Ther 2010; 23: 137-43.
  6. Del Valle MC, Loebel AD, Murray S, Yang R, Harrison DJ, Cuffel BJ. Change in Framingham risk score in patients with schizo- phrenia: a post hoc analysis of a randomized, double-blind, 6-week trial of ziprasidone and olanzapine. Prim Care Compan- ion J Clin Psychiatry 2006; 8: 329-33. de Padua Netto MV, Bonfim TC, Costa EN, de Lima HV, Netto LC. Cardiovascular risk estimated in renal transplant recipients with the Framingham score. Transplant Proc 2012; 44: 2337-40.
  7. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Fram- ingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004; 23: 625-30.
  8. Erem C, Arslan C, Hacıhasanoğlu A, Değer O, Topbaş M, Ukinc K, et al. Prevalence of obesity and associated risk factors in a Turkish population (Trabzon city, Turkey). Obes Res 2004; 12: 1117-27.
  9. Ünal B, Sözmen K, Uçku R, Ergör G, Soysal A, Baydur H, et al. High prevalence of cardiovascular risk factors in a Western urban Turkish population: a community-based study. Anadolu Kardiyol Derg 2013; 13: 9-17.
  10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-52
  11. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
  12. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, et al. Diagnostic criteria for dyslipidemia. Ex- ecutive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007; 14: 155-8.
  13. Alberti KG, Zimmet PZ. Definition, diagno